Orthopedics This Week

Will a $95 Million Deal Bring Chemonucleolysis Back?

Informações:

Sinopsis

Is chemonucleolysis for painful lower back disc herniation returning? In the 1980s chymopapain achieved fairly wide spread use as a chemonucleolysis agent. Outcomes were highly technique and patient selection dependent. It eventually left the market. Now two large firms have inked a deal to bring a new chemonucleolysis approach to market. Will this one work?